The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ADC Therapeutics, Inc. Common H0036K147 5,322 218,027 SH   SOLE   218,027 0 0
Cullinan Management, Inc. Common 230031106 329,772 7,913,887 SH   SOLE   7,913,887 0 0
Epizyme, Inc. Common 29428V104 20,308 2,331,534 SH   SOLE   2,331,534 0 0
G1 Therapeutics, Inc. Common 3621LQ109 22,323 927,794 SH   SOLE   927,794 0 0
Harpoon Therapeutics, Inc. Common 41358P106 81,555 3,898,422 SH   SOLE   3,898,422 0 0
iTeos Therapeutics, Inc. Common 46565G104 80,513 2,355,557 SH   SOLE   2,355,557 0 0
MEI Pharma, Inc. Common 552798202 34,773 10,137,859 SH   SOLE   10,137,859 0 0
Merus N.V. Common N5749R100 14,641 700,879 SH   SOLE   700,879 0 0
Oncorus, Inc. Common 68236R103 33,088 2,377,031 SH   SOLE   2,377,031 0 0
Repare Therapeutics, Inc. Common 760273102 63,521 2,069,749 SH   SOLE   2,069,749 0 0
TCR2 Therapeutics, Inc. Common 87808K106 74,431 3,370,982 SH   SOLE   3,370,982 0 0
Turning Point Therapeutics, Inc. Common 90041T108 25,462 269,186 SH   SOLE   269,186 0 0
YmAbs Therapeutics, Inc. Common 984241109 10,200 337,291 SH   SOLE   337,291 0 0